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Abstract
Polycystic ovary syndrome (PCOS) is a complex endocrine disorder characterized by hyperandrogenism and insulin
resistance, both of which have been connected to atherosclerosis. Indeed, an increased risk of clinical manifestations of
arterial vascular diseases has been described in PCOS. On the other hand endothelial dysfunction can be detected early on,
before atherosclerosis develops. Thus we assumed that vascular dysfunction is also related directly to the hormonal
imbalance rather than to its metabolic consequences. To detect early functional changes, we applied a novel rodent model
of PCOS: rats were either sham operated or hyperandrogenism was achieved by implanting subcutaneous pellets of
dihydrotestosterone (DHT). After ten weeks, myograph measurements were performed on isolated aortic rings. Previously
we described an increased contractility to norepinephrine (NE). Here we found a reduced immediate relaxation to estradiol
treatment in pre-contracted aortic rings from hyperandrogenic rats. Although the administration of vitamin D3 along with
DHT reduced responsiveness to NE, it did not restore relaxation to estradiol. Poly-(ADP-ribose) polymerase (PARP) activity
was assessed by poly-ADP-ribose immunostaining. Increased PAR staining in ovaries and circulating leukocytes from DHT
rats showed enhanced DNA damage, which was reduced by concomitant vitamin D3 treatment. Surprisingly, PAR staining
was reduced in both the endothelium and vascular smooth muscle cells of the aorta rings from hyperandrogenic rats. Thus
in the early phase of PCOS, vascular tone is already shifted towards vasoconstriction, characterized by reduced
vasorelaxation and vascular dysfunction is concomitant with altered PARP activity. Based on our findings, PARP inhibitors
might have a future perspective in restoring metabolic disorders in PCOS.
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Introduction
Polycystic ovary syndrome (PCOS) is the most common
endocrine disorder, affecting 4–11% of women. The lifelong
disease often remains hidden because of its multidisciplinarity. The
main problem is infertility but the disease influences the whole
body in many different ways [1]. In complete fenotype PCOS is
manifested with hyperandrogenism, ovulatory dysfunction and
polycystic ovaries. Two of these are the diagnostic criteria for
PCOS as the Rotterdam 2003 criteria defined it. As a metabolic
component insulin resistance plays role in the disorder and obesity
accompanies it in 50–60% of the cases. These two with other
developing risk factors such as metabolic syndrome, hypertension
and diabetes mellitus together put women with PCOS at a high
risk for cardiovascular diseases [2]. This was proved by Christian
et al. in 2003, when coronary artery calcium, a marker for
coronary arteriosclerosis, was measured by electron beam
computed tomography in women with PCOS and without PCOS
at similar age. The results showed PCOS women were increased
risk for atherosclerosis as coronary artery calcium was more
prevalent in them then in control group from obesity [3].
Indeed, haemodynamic changes of internal carotid artery [4]
and early predictors of endothelium dysfunction in women with
PCOS were detected, as FMD (flow mediated dilatation) and
nitrate-mediated dilation were significantly lower in women with
PCOS than in the control group [5]. Moreover, a recent meta-
analysis found a two-fold risk of coronary heart disease and stroke
for patients with PCOS compared to women without PCOS [6].
Estrogens have a multiple cardiovascular protective effect.
These include both a rapid and a long-term vasorelaxing effect,
the latter of which depends on gene expression and employs
different signalling pathways not as in short term effects [7],[8]. In
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PCOS either the relative or the absolute absence of estrogens
might contribute to the higher cardiovascular risk.
Vitamin D was effective in PCOS: a daily intake of vitamin D
reduced obesity in PCOS patients [9], however oral vitamin D
treatment did not improve insulin resistance [10].
Poly-(ADP-ribose) polymerase-1 (PARP-1) is a ubiquitously
expressed nuclear enzyme, which has a central role in responses to
cellular injury [11]. PARP-1 is activated by the presence of single
strand DNA. PARP-1 cleaves NAD into nicotinamide and ADP-
ribose, and attaches polymers of the latter product to nuclear
acceptor proteins including histones, transcription factors, and the
PARP itself. Through PARylation PARP regulate DNA repair by
attracting DNA ligase III to the DNA. On the other hand,
overactivation of PARP consumes NAD, resulting in decreased
glycolysis, electron transport and ATP formation. While the
activation of PARP-1 by limited, sub-lethal injury may facilitate
DNA repair and cell survival, irreparable DNA damage triggers –
either apoptotic or necrotic – cell death [11].
This signalling pathway has been implicated in both experi-
mental models and in human cardiovascular diseases [12], [13].
PAR polymerisation has been proved in several clinical settings; in
patients suffering from myocardial infarction and therapeutic
revascularization, PARP activation was detected in circulating
leukocytes [14], [15]. Activation of PARP was also demonstrated
in the failing hearts by an increased abundance of poly-ADP
ribosylated proteins when immunohistochemical analysis revealed
that PARP activation was localized to the nucleus of the
cardiomyocytes from the failing hearts [16]. In different rodent
models of diabetic cardiomyopathy, a significant increase in (poly-
ADP)-ribosylation was detected in cardiac myocites and endothe-
lial cells, which were remarkably improved by PARP inhibitors
[17], [18]. Poly(ADP-ribose polymerase-1 regulation was detected
in the progression of autoimmune nephritis by inducing necrotic
cell death and modulating inflammation [19]. In a phase II
prospective, single-blind, multi-centre, dose escalation study of a
single dose of intravenous PARP inhibitor (INO-1001) (200 mg,
400 mg, or 800 mg) was administered to 30 patients between the
ages of 48 and 63 years with acute ST-segment elevation
myocardial infarction (STEMI), who were to be treated with
primary percutaneous coronary intervention (PCI). The PARP
inhibitor INO-1001 was found to induce a tendency to reduce the
plasma levels of C-reactive protein and the inflammatory marker
IL-6, No drug-related serious adverse events were observed in the
patients receiving the drug during the study period [20]. Based on
the above mentioned facts, we hypothesized that PARP-1 may be
activated in PCOS as well.
Besides the available pharmacological inhibitors, there is
cumulating amount of evidence for endogenous modulators, too.
Recently the active forms of vitamin D3 has been shown to inhibit
PARP by Mabley et al., it was demonstrated that UV irradiation-
mediated PARP activation in human keratinocytes can be
inhibited by treatment with vitamin D, 7-dehydrocholesterol or
1alpha,25-dihydroxyvitamin D3 [21]. Interestingly, a gender
difference was described in the PARP-1 activity, Mabley et al.
[22] showed that gender specific inflammatory response is
preferencially downregulated by PARP in male but not in female
animals. This was proven in stroke, as McCullogh found that
PARP inhibition and PARP-1 deficiency conferred their protec-
tion only in male mice, they had no benefit to the female ones in
cerebral ischaemic damage [23].
The same group examined the downstream mediators of NO/
PARP activation to investigate possible mediators of ischemic
sexual dimorphism. Apoptosis inducing factor translocation and
PAR formation did not mediate ischemic injury in the female mice
brain; although equivalent activation of cell death pathway
occurred in both sexes after ischemia, detrimental effects were
only present in males [24].
The aim of this study was to show altered regulation of vascular
tone in PCOS applying a novel rodent model. We wanted to
detect the possible beneficial effect of chronic vitamin D
administration and acute estradiol treatment. Also we aimed to
look at altered DHT induced PAR response in different organs
and sought to identify a correlation between the changes in
vascular reactivity and PAR responses.
Methods
Ethics approval The investigation conforms to the Guide for
the Care and Use of Laboratory Animals published by the US
National Institutes of Health and was approved by Semmelweis
University Animal Care Commission (IRB approval: 22.1/2960/
003/2009).
Animals
The investigation conforms to the Guide for the Care and Use
of Laboratory Animals published by the US National Institutes of
Health and was approved by Semmelweis University Animal Care
Commission (IRB approval: 22.1/2960/003/2009) conforming to
the Institutional Animal Care and Use Committee (IACUC).
Thirty adolescent, 21–28 day-old, female Wistar rats, weighing
100–140 g were purchased from Semmelweis University Animal
Colony (Budapest, Hungary, originated from Charles River Ltd).
Figure 1. Estradiol dependent vasorelaxation is weaker in
experimental PCOS. Rats were treated with DHT for 70 days +/2
vitamin D3 when they were sacrificed and aorta rings were isolated for
myography studies. Specimens were first precontracted with norepi-
nephrine (561028 M) and then treated with two different doses of
estradiol as shown. Vasodilation is expressed as a percentage of
difference between maximally contracted and maximally dilated tone of
the vessels according to the following equation (percentage= (tension
after norepinephrine-tension after estradiol)/(tension after norepineph-
rine-baseline tension) * 100). The difference between control and DHT
(#=p,0.01) or control vs. DHT+ D3 animals (+=p,0.01) were both
significant. The difference between DHT and DHT+ D3 was not
significant.
doi:10.1371/journal.pone.0055589.g001
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The animals were randomized into 3 treatment groups: control,
DHT and DHT+vitamin D3. No medical or surgical complica-
tions were observed throughout the whole period. Conventional
rat chow and tap water were provided ad libitum. All surgery was
performed under sodium pentobarbital anesthesia, and all efforts
were made to minimize suffering.
Experimental PCOS model and the treatment procedures
To induce experimental PCOS, twenty animals received 70-
day-long continuous-release subcutaneous pellets of 7.5 mg
dihydro-testosterone (DHT, Innovative Research of America,
Sarasota, Fl, USA) underneath the back skin, releasing a daily dose
of 83 mg DHT as described by Manneras et al. [25]. Rats were
anesthetized with 45 mg/kg sodium pentobarbital (Nembutal,
Phylaxia-Sanofi, Budapest, Hungary). Ten animals underwent
sham operations (control group). Following the chronic surgical
interventions, 20 mg amoxicillin +4 mg clavulanic acid combina-
tion (Augmentin GlaxoSmithKline, Memphis, USA) was admin-
istered intramuscularly. Ten animals from the DHT group
received subcutaneously 120 ng/100 g body weight 1,25-dihy-
droxy-vitamin D3 (DHT+ D3 group, Inj. Calcijex, 2 mg/ml,
Abbott Lab., Illinois, USA) every week, which is a slight
modification of the protocol previously described by Przybylski
et al. [26]. Our choice of weekly administration was preferred
instead of the previously described daily injections to minimize
stress. Animals in the control and the DHT group received vehicle
subcutaneously (saline). Chronic treatments were continued for
70 days before the conclusion of the experiments with ex vivo
measurements.
Chemicals and reagents
Normal Krebs-Ringer (nKR) solution was composed of (in
mM): 119 NaCl, 4.7 KCl, 2.5 CaCl2, 1.17 MgSO4, 20 NaHCO3,
1.18 KH2PO4, 0.027 EDTA, and 11 glucose (Sigma Aldrich St.
Louis, MO, USA and Budapest, Hungary). Hyperkalaemic
solution was prepared from normal KR. It was supplemented
with KCl to achieve 124 mM potassium level. Temperature of the
solution was kept at 37uC, and it was aerated with a 5% CO2/
95% O2 mix (Lindegas, Re´pcelak, Hungary). Norepinephrine and
17- estradiol were obtained from Sigma-Aldrich. Drugs were
freshly prepared in nKR solution on the day of the experiment.
Ex vivo pharmacological reactivity of thoracic aorta rings
After 70 days of treatment, rats were anesthetized. For
anesthesia we used penthobarbital (Nembutal, Phylaxia-Sanofi,
Budapest, Hungary) 45 mg/kg intraperitoneally. Animals were
perfused transcardially with 10 ml heparinized (10 IU/ml) nKR
solution. The aorta of each animal was then removed. The distal
part of the thoracic aorta (TA) was isolated and four rings were
prepared and placed into a vessel chamber filled with nKR
solution aerated with 95% O2/5% CO2 mix. Thoracic aorta
segments of 3 mm length from each experimental group were
mounted on stainless steel vessel holders (200 mm in diameter) of a
conventional myograph setup (610-M Multi Myograph System;
Figure 2. PAR staining is reduced in both the endothelium and the smooth muscle cells of aortas in PCOS. Ovaries, aortas and
circulating leukocytes were isolated from animals exposed to the three treatments (control, DHT, DHT+ D3) as described previously. PAR
immunohistochemistry was performed. Representative images were taken. PAR staining was augmented in ovaries and leukocytes, however was
reduced in both the endothelial and the muscular layer of the aortas in the DHT animals. Vitamin D3 reduced the augmented staining detected in
ovaries and leukocytes, but did not alter the staining in the aortas. It is notable that the DHT treatment induced the morphological changes typical in
PCOS.
doi:10.1371/journal.pone.0055589.g002
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Danish Myo Technology, Aarhus, Denmark). The organ cham-
bers of the myographs were filled with 8 ml of nKR solution. The
bath was warmed to 37uC, and the resting tension of TA rings was
adjusted to 15 mN, according to previous studies [27].
Segments were exposed to 124 mM K+ to elicit a reference
contraction. Twenty minutes later, precontraction was induced by
norepinephrine (561028 M) and for estradiol-mediated vasore-
laxation cumulative dose-response measurements were used
(1025–1024 M). Norepinephrine contraction was expressed as a
percentage of K+-precontraction. Aortic relaxations were tested
after a stable plateau of contraction had been reached. Relaxant
responses were expressed as a percentage of the precontraction
produced by norepinephrine (percentage = (tension after norepi-
nephrine-tension after estradiol)/(tension after norepinephrine-
baseline tension) * 100). The isometric tension recording of the
thoracic aorta segments was made with the MP100 system, and
recorded data were analyzed with AcqKnowledge 3.7.3 software
(BIOPAC Systems, Goleta, CA). Vasoactive substances were
dissolved in nKR. All concentrations are expressed as the final
concentration in the organ bath.
Histology
Ovaries and aorta rings of the animals were collected and
freshly fixed for histological examinations. Tissue samples were
immersion fixed in 4% buffered formaldehyde, hematoxylin-eosin
staining was prepared and specimens were examined using a Zeiss
AxioImager. A1 microscope coupled with Zeiss AxioCAm MRc5
CCD camera for evaluation Pannoramic viewer software was
used; 3DHISTECH Ltd., Budapest, Hungary.
Immunohistochemistry
Leucocytes were isolated from venous blood samples using
Histopaque-1083 (Sigma Aldrich, St Louis, MO, USA). Methanol-
fixed smears were prepared from the cell suspension. Samples of
ovaries and aortas were fixed with formalin, embedded in paraffin
and 5 mm thick sections were prepared.
After deparaffinization and antigen retrieval (0.1 mmol/l citrate
buffer, pH 3, heated in a microwave oven for 15 min), samples
were incubated with a mouse monoclonal anti-poly-ADP-ribose
(PAR) antibody overnight at 4uC (Calbiochem, San Diego, CA,
USA, 1:1,000). Secondary labelling was achieved using biotiny-
lated anti-mouse horse antibody (Vector Laboratories, Burlin-
game, CA, USA) (30 min, room temperature). Horseradish
peroxidase-conjugated avidin (30 min, room temperature) and
nickel-enhanced diaminobenzidine (6 min, room temperature,
black color) was used (Vector Laboratories). Tissue sections and
smears were counterstained with nuclear fast red.
To evaluate PAR-staining, the following semiquantitative score
system was applied by a blinded observer as described previously
[28], [29]. The semiquantitive evaluation scoring system was: 1
point: no staining; 2 points: light cytoplasmic staining; 3 points:
strong cytoplasmic staining; 4 points: cytoplasmic staining with a
few positive nuclei; 5 points: approximately 50% of the nuclei
positive; 6 points: approximately 75% of the nuclei positive; 7
points: general nuclear staining with a few negative cells; 8 points:
all nuclei positive; 9 points: strong nuclear staining in all cells; 10
points: very strong general nuclear staining in all cells. In case of
leukocyte smears 5 fields were evaluated with a minimum of 300
cells. In case of arteries and ovaries, the whole tissue section was
examined.
Figure 3. Statistical analysis confirmed the significant changes in PAR staining intensities in the three experimental groups. Slides
from Figure 2. were evaluated using a 10-graded scale (PAR score) as described in Methods. Results from ovaries (A), circulating leukocytes (B),
vascular endothelium (C) and vascular smooth muscle cells (D) are presented. Figure 3. A, B: Control vs. DHT (#=p,0.05), DHT vs. DHT+ D3
(6=p,0.05). Figure 3. C, D: Control vs. DHT, and Control vs. DHT+ D3 (#=p,0.05).
doi:10.1371/journal.pone.0055589.g003
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Statistical analysis
Parametric variables were analyzed by applying ANOVA. As a
post hoc test, Newman-Keuls` test was applied. P,0.05 was
uniformly accepted as a significant difference. Data were presented
as mean 6 SEM.
Results
Acute estrogen treatment induces a weaker
vasorelaxation in aortas from hyperadrogenic animals
To examine the vascular dysfunction in the early phase of
polycystic ovary syndrome (PCOS) we first treated rats with
dihydrotestosterone (DHT) for 70 days as described by Manneras
et al. [25]. A subgroup of animals was simultaneously treated with
vitamin D3 (Figure 1). Histology of the ovaries from DHT-treated
rats showed a polycystic morphology, which was not altered by the
administration of vitamin D (see later in the Results section and
Figure 2).
Ex vivo experiments were performed on excised aorta rings. As
a control, the aorta rings were first challenged with hyperkalaemia
(total extracellular potassium 124 mM) and showed similar
contractility in all treatment groups. Since the relative hypoestro-
genic state in PCOS is considered to contribute to the vascular
dysfunction we asked whether acute estrogen treatment can
restore normal vascular tone. To explore this, aorta rings were
precontracted with norepinephrine (561028 M) for approximately
15 minutes and then were treated with estradiol (E2: 1025–
1024 M incubation approximately 25 minutes to let the signal
transduction process work). Estradiol readily induced vasorelax-
ation in the precontracted aortas. Surprisingly this effect was
significantly weaker in the DHT group compared to the control
group. Vitamin D3 did not restore the vascular responsiveness to
estradiol, namely E2 induced a similar relaxation in the
DHT+vitamin D3 as in the DHT alone group. (Figure 1. Control
vs. DHT+D3 p,0.05; DHT vs. DHT+D3 ns,). Thus short-term
estrogen treatment is less potent as a vasorelaxing agent in large
arteries from hyperandrogenic animals. In the rat aortas treated by
dihydrotestoterone, the estradiol dependent vasorelaxation was
substantially reduced (p,0.01) compared to the control group,
and vitamin D3 treatment could not correct it (Figure 1).
PARP activity is selectively regulated in different tissues
in hyperandrogenic states
PARP activity is a marker of cellular DNA damage, and it was
also shown to be controlled by estrogens [12]. PARP activity can
be monitored by the amount of poly-ADP-ribosylated (PAR)
proteins. Tissue samples from control, DHT and DHT+vitamin
D3 groups were collected, histology and immunohistochemistry –
using PAR-antibody – were performed. Samples were evaluated
according to a 10-grade semiquantitive scale [29]. In control
animals we found similar PAR staining in the different tissues –
circulating leukocytes, ovaries, endothelium, vascular smooth
muscle cells. When the different treatment groups were compared
we have found two distinct patterns: the DHT treatment enhanced
PARP-activity in the ovaries and the circulating leukocytes, which
was inhibited by vitamin D3 (Figure 2. and Figure 3. A, B; Control
vs. DHT p,0.05, DHT vs. DHT+D3 p,0.05,). On the contrary,
in the vascular endothelium and smooth muscle cells the PAR
staining in the DHT group was significantly weaker (Figure 2. and
Figure 3. C, D; Control vs. DHT and Control vs. DHT+D3
p,0.05).
Discussion
Our experiment has been the first to study the relaxing capacity
of estradiol on the vessel wall under a hyperandrogenic milieu and
the effect of vitamin D3 therapy on it in a recent rodent model of
PCOS. Parallelly, we were detecting the DHT-induced PAR
response, PAR poly(adenosinphosphate-ribose) accumulation and
the effect of vitamin D3 therapy on it in different organs to assess
the activation and inhibition of PARP enzyme in our PCOS
simulating clinical circumstances.
In women with PCOS significant pharmacological reactivity
changes develop as well as mechanical damages of the large blood
vessels [3], [4]. The changes in smooth muscle and endothelium
related relaxation, as well as vasoconstriction, were studied in
PCOS and in hyperandrogenic circumstances. Kravariti measured
a significant decrease in both endothel dependent (FMD), and
smooth muscle related (nitrate mediated) relaxation compared to
the normal controls [5].
Estrogen has a variety of effects on vasculature including the
regulation of vascular tone. The vasodilatory effects of estrogen
can be endothelium dependent and independent, and they can
work by genomic and nongenomic mode of action [30]. Estrogen
receptors are present in all components of the blood vessel wall:
endothelium, smooth muscle and adventitia [31]. The vasodilatory
capacity of estrogen is well documented both in vivo and in vitro.
Andersen et al. differentiated the long term and acute vasomotor
responses to estradiol in rat aorta: the long term effect was
mediated through the endothelium mostly by increasing NO
release, but the acute effect of estradiol seemed to be brought on
through an effect of vascular smooth muscle cells. Developed
contraction of different contractile agents had been reduced by the
effect of both long-term and acutely given estradiol, but in varying
degrees [32].
Testosterone also has a moderate vasorelaxant effect acutely,
especially by the modulation of vascular smooth muscle ion
channel function, particularly the inactivation of L- type voltage
operated Ca2+ channels and/or activating voltage – operated Ca2+
and K+ channels [33]. Torres et al. investigated the modulation of
aortic vascular reactivity by sex hormones in a male rat model of
metabolic syndrome. He found that testosterone caused endothe-
lial dysfunction and he detected a protective effect of castration, or
of estradiol, given to the castrated animals [34]. There is no data
in polycystic ovary syndrome and only a few items of data are
available of the effects of estrogen on blood vessels in a
hyperandrogenic milieu.
In our study we found an impaired vasorelaxant effect of
estrogen. Athough it was still working, the vasorelaxant effect was
substantially reduced in hyperandorgenic milieu caused by the
PCOS (Figure 1). New’s [35] results showed that the positive
cardiovascular effects of estrogen do not manifest themselves in a
hyperandrogenic medium. Compared to the control men group,
there were no difference in arterial compliance, blood pressure,
cholesterol levels and cardiovascular risk altogether in estradiol
treated male-to-female transsexuals. Our results correlate with
results of New’s studies. Li et al. found that estrogen potentiates
the constrictor prostanoid function in female rat aorta by
upregulation of the cyclooxygenase-2 and thromboxane pathways
both in the endothelium and vascular smooth muscle by
upregulating the expression of thromboxan receptors in vascular
smooth muscle comparing to males and ovariectomized females
[36].
Our immunhistochemical analysis showed the expected DHT-
induced PAR-response in the different tissues regarding ovary and
leukocytes. The DHT-induced PAR-response increased in DHT
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treated animals and vitamine D3 therapy reduced it significantly.
(Figure 3. A, B) But in the aorta, both in the endothelium or the
vascular smooth muscle, the DHT induced PAR-response was
significantly reduced by DHT treatment and vitamin D3 did not
influence it any more (Figure 3. C, D). Similar regional difference
was observed in the effect of insulin in PARP activity. Insulin
lowered PARP activity in leukocytes, however, it did not influence
the placenta and umbilical artery [28]. This regional difference
might be the compensatory, protective effect of DHT – as
described by Xu et al. on HUVEC culture. They found a decrease
in the activity of oxydative stress enzymes, caspase-3 and -9 in
endothelial cells, following DHT pretreatment [37].
There are emerging evidences about several endogeneous and
exogeneous modulatory factors on PARP activity; including
estrogen and the active forms of vitamin D as PARP inhibitor [38].
As it was detected in many clinical conditions but not in
policystic ovary syndrome, we studied the PAR activation in a
rodent model of PCOS. In PCOS the cardiovascular risk is
elevated as unfavourable hormonal – hyperandrogenic, metabolic,
prediabetic and inflammatory alterations are present from a
younger age till menopause [39]. We also wanted to examine the
inhibitory capacity of vitamin D3 on poly (ADP-ribose) polymerase
compared to controls and DHT treated animals.
Our results were coherent with earlier studies in hypertension
and diabetes mellitus [12], [13], [38], [40] as DHT treatment
increased poly(ADP-ribolysation) in the ovarium and leukocytes in
concordance with the clinical state of elevated risk of hypertension
and diabetes mellitus in PCOS. Further studies are needed to
clarify the role of PARP in developing hypertension, diabetes
mellitus and cardiovascular damage in PCOS, but our study could
be the first step in this direction.
To sum up, the activation of the poly(ADP-ribose) polymerase
was shown in many different clinical and pathological settings
(chronic inflammation, autoimmune diseases e.g.;arthritis, colitis),
vascular diseases (atherosclerotic plaques, in microvessels in
diabetic patients) ischaemic diseases (myocardial infarction, bypass
surgery, stroke), and in chronic heart failure [13], but in PCOS it
had not been examined before. In our measurements, the detected
elevation of PARP activation in the leukocytes and the ovaries of
polycystic ovary syndrome induced rats proved our hypothesis, as
it was similar in other pathological conditions. On the contrary,
DHT treatment significantly reduced PARP activity both the
endothelial and smooth muscle layer of the aorta and Vitamin D3
treatment did not have any significant influence on this effect.
Conclusions
The DHT treatment caused alterations in relaxant capacity.
Estrogen in hyperandrogenic milieu could not work as well as in
the control female rat aortic rings and the influence of vitamin D3
on them was not significant. This result might give the clue to one
of the key-mechanisms of early cardiovascular damage in PCOS.
In PCOS, caused by DHT treatment, deleterious effects were
exerted partly via PARP activity (ovaries and leukocytes), and
these could be reversed by vitamin D. But in aortic walls, both in
endothelium or vascular smooth muscle, the PARP activity was
significantly reduced by DHT treatment and vitamin D3 did not
influence it significantly. Similarities of PARP expression and
estrogen dependent relaxation may raise the possibility of causal
connections, which require further investigation.
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